ABSTRACT
OBJECTIVE: To describe the laboratory parameters and biomarkers of the cytokine storm syndrome associated with severe and fatal COVID-19 cases. METHODS: A search with standardized descriptors and synonyms was performed on November 28th, 2020 of the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, LILACS, and IBECS to identify studies of interest. Grey literature searches and snowballing techniques were additionally utilized to identify yet-unpublished works and related citations. Two review authors independently screened the retrieved titles and abstracts, selected eligible studies for inclusion, extracted data from the included studies, and then assessed the risk of bias using the Newcastle-Ottawa Scale. Eligible studies were those including laboratory parameters-including serum interleukin-6 levels-from mild, moderate, or severe COVID-19 cases. Laboratory parameters, such as interleukin-6, ferritin, hematology, C-Reactive Protein, procalcitonin, lactate dehydrogenase, aspartate aminotransferase, creatinine, and D-dimer, were extracted from the studies. Meta-analyses were conducted using the laboratory data to estimate mean differences with associated 95% confidence intervals. DATA SYNTHESIS: The database search yielded 9,620 records; 40 studies (containing a total of 9,542 patients) were included in the final analysis. Twenty-one studies (n = 4,313) assessed laboratory data related to severe COVID-19 cases, eighteen studies (n = 4,681) assessed predictors for fatal COVID-19 cases and one study (n = 548) assessed laboratory biomarkers related to severe and fatal COVID-19 cases. Lymphopenia, thrombocytopenia, and elevated levels of interleukin-6, ferritin, D-dimer, aspartate aminotransferase, C-Reactive-Protein, procalcitonin, creatinine, neutrophils and leucocytes were associated with severe and fatal COVID-19 cases. CONCLUSIONS: This review points to interleukin-6, ferritin, leukocytes, neutrophils, lymphocytes, platelets, C-Reactive Protein, procalcitonin, lactate dehydrogenase, aspartate aminotransferase, creatinine, and D-dimer as important biomarkers of cytokine storm syndrome. Elevated levels of interleukin-6 and hyperferritinemia should be considered as red flags of systemic inflammation and poor prognosis in COVID-19.
Subject(s)
Biomarkers/blood , COVID-19/pathology , Cytokine Release Syndrome/diagnosis , C-Reactive Protein/analysis , COVID-19/complications , COVID-19/mortality , COVID-19/virology , Cytokine Release Syndrome/etiology , Ferritins/blood , Humans , Interleukin-6/blood , Leukocytes/cytology , Leukocytes/metabolism , SARS-CoV-2/isolation & purification , Severity of Illness IndexABSTRACT
OBJECTIVE: To assess the effects of bilingualism compared to monolingualism on the clinical manifestation of Alzheimer's disease. METHODS: We searched the databases: MEDLINE, The Cochrane Central Register of Controlled Trials, Embase and LILACS, and searched by hand and in gray literature for studies published before September 2019. The quality of included studies was assessed using the Newcastle-Ottawa Scale. Two reviewers independently searched for studies, extracted data, and performed the quality assessment. RESULTS: Eight studies were included in this review. Data from meta-analyses suggest that bilingual individuals with Alzheimer's disease exhibit symptoms (694 participants; mean difference (MD) (4.05 years; 95% CI: 1.87-6.22 and are diagnosed later (1012 participants; MD 2.0 years; 95% CI: 0.08-3.92) than monolingual participants. CONCLUSION: Bilingualism may delay the manifestation of symptoms and diagnosis of Alzheimer's disease. Further studies with more rigorous methodology are needed to improve the precision of the results.
Subject(s)
Cognitive Reserve , Alzheimer Disease , Meta-Analysis , Multilingualism , Systematic ReviewABSTRACT
OBJECTIVE: To assess the effects of bilingualism compared to monolingualism on the clinical manifestation of Alzheimer's disease. METHODS: We searched the databases: MEDLINE, The Cochrane Central Register of Controlled Trials, Embase and LILACS, and searched by hand and in gray literature for studies published before September 2019. The quality of included studies was assessed using the Newcastle-Ottawa Scale. Two reviewers independently searched for studies, extracted data, and performed the quality assessment. RESULTS: Eight studies were included in this review. Data from meta-analyses suggest that bilingual individuals with Alzheimer's disease exhibit symptoms (694 participants; mean difference (MD) (4.05 years; 95% CI: 1.87-6.22 and are diagnosed later (1012 participants; MD 2.0 years; 95% CI: 0.08-3.92) than monolingual participants. CONCLUSION: Bilingualism may delay the manifestation of symptoms and diagnosis of Alzheimer's disease. Further studies with more rigorous methodology are needed to improve the precision of the results.
